US cell therapies firm Promethera secures investment from ITOCHU
ITOCHU is the first lead investor in Promethera’s new investment round, which is expected to be completed in the first quarter of this year. The US pharma firm is
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) indicated to treat patients who use hemodialysis or peritoneal dialysis. It will help induce coordinated erythropoiesis, increase red blood